Recombinant C-terminal fragments of the gastrin-releasing peptide precursor are bioactive

Cancer Lett. 2007 Aug 28;254(1):87-93. doi: 10.1016/j.canlet.2007.02.014. Epub 2007 Mar 29.

Abstract

C-terminal fragments from the precursor for gastrin-releasing peptide (GRP) have been detected in several human tumour types. We have previously demonstrated that recombinant human proGRP42-98 is biologically active. To investigate the regions responsible, proGRP42-98 was cleaved with thrombin, and the fragments purified by HPLC. Both proGRP42-79 and proGRP80-98 stimulated proliferation of the human colorectal carcinoma cell line DLD-1, but neither peptide bound to the GRP receptor or bombesin receptor subtype 3. We conclude that two distinct regions of the proGRP C-terminus are biologically active, via a receptor distinct from the known GRP receptors. This discovery opens the way for the development of selective antagonists that may offer new therapies for proGRP-producing tumours.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • BALB 3T3 Cells
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Chromatography, High Pressure Liquid
  • Humans
  • Mice
  • Peptide Fragments / genetics
  • Peptide Fragments / metabolism
  • Peptide Fragments / pharmacology*
  • Peptides / chemistry
  • Peptides / metabolism*
  • Protein Binding
  • Protein Precursors / chemistry
  • Protein Precursors / metabolism*
  • Radioligand Assay
  • Receptors, Bombesin / genetics
  • Receptors, Bombesin / metabolism
  • Recombinant Proteins / isolation & purification
  • Recombinant Proteins / metabolism
  • Recombinant Proteins / pharmacology*
  • Transfection

Substances

  • Peptide Fragments
  • Peptides
  • Protein Precursors
  • Receptors, Bombesin
  • Recombinant Proteins
  • bombesin receptor subtype 3
  • gastrin-releasing peptide precursor